Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 2, 2011, Pages 333-338

  Agerso H ^a   Brophy, D F ^b   Pelzer, H ^a   Martin, E J ^b   Carr, M ^c   Hedner, U ^d   Ezban, M ^a  

^a NOVO NORDISK A S   (Denmark)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c NOVO NORDISK INC   (United States)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Clearance; Hemophilia patients; Modeling; NONMEM; Pharmacokinetics; RFVIIa

Indexed keywords

ANTIGEN; ANTITHROMBIN III; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLOOD CLOT; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; ENZYME IMMUNOASSAY; HEMOPHILIA; HUMAN; PRIORITY JOURNAL;

ANTIGENS; ANTITHROMBINS; FACTOR VIIA; HEMOPHILIA A; HUMANS; IMMUNOENZYME TECHNIQUES; INFUSIONS, INTRAVENOUS; RECOMBINANT PROTEINS;

EID: 79251554994     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.04152.x     Document Type: Article

References (28)

1. Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002; 99: 923-30.
2. Lisman T, de Groot PG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost 2003; 1: 1138-9.
3. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7.
4. Allen GA, Persson E, Campbell RA, Ezban M, Hedner U, Wolberg AS. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 2007; 27: 683-9.
5. Weeterings C, de Groot PG, Adelmeijer J, Lisman T. The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface. Blood 2008; 112: 3227-33.
6. Erhardtsen E, Nilsson P, Johannessen M, Thomsen MS. Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects. J Clin Pharmacol 2001; 41: 880-5.
7. Klitgaard T, Nielsen TG. Overview of the human pharmacokinetics of recombinant activated factor VII. Br J Clin Pharmacol 2008; 65: 3-11.
8. Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-48.
9. Klitgaard T, Palacios R, Boffard KD, Iau PT, Warren B, Rizoli S, Rossaint R, Kluger Y, Riou B. Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding. Crit Care 2006; 10: R104.
10. Beeby TL, Chasseaud LF, Taylor T, Thomsen MK. Distribution of the recombinant coagulation factor 125I-rFVIIa in rats. Thromb Haemost 1993; 70: 465-8.
11. Seested T, Nielsen HM, Christensen EI, Appa RS. Cellular and intracellular distribution of recombinant activated factor VII in the rat liver. Thromb Haemost 2010;103: 860-2.
12. Rao LV, Pendurthi UR. Factor VIIa binding to endothelial cell protein C receptor. Thromb Res 2008; 122(Suppl 1): S3-6.
13. Gopalakrishnan R, Hedner U, Ghosh S, Nayak RC, Allen TC, Pendurthi UR, Rao LV. Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa). J Thromb Haemost 2010; 8: 301-10.
14. Petersen LC, Elm T, Ezban M, Krogh TN, Karpf DM, Steino A, Olsen EH, Sorensen BB. Plasma elimination kinetics for factor VII are independent of its activation to factor VIIa and complex formation with plasma inhibitors. Thromb Haemost 2009; 101: 818-26.
15. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing 2009. Available from: URL:
16. Fair DS. Quantitation of factor VII in the plasma of normal and warfarin-treated individuals by radioimmunoassay. Blood 1983; 62: 784-91.
17. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
18. Wildgoose P, Nemerson Y, Hansen LL, Nielsen FE, Glazer S, Hedner U. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 1992; 80: 25-8.
19. Spiezia L, Rossetto V, Campello E, Gavasso S, Woodhams B, Tormene D, Simioni P. Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis. Thromb Haemost 2010; 103: 1188-92.
20. Bysted BV, Scharling B, Moller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation. Haemophilia 2007; 13: 527-32.
21. Hjortoe G, Sorensen BB, Petersen LC, Rao LV. Factor VIIa binding and internalization in hepatocytes. J Thromb Haemost 2005; 3: 2264-73.
22. Lawson JH, Butenas S, Ribarik N, Mann KG. Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. J Biol Chem 1993; 268: 767-70.
23. Olson ST, Swanson R, Raub-Segall E, Bedsted T, Sadri M, Petitou M, Herault JP, Herbert JM, Bjork I. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin. Thromb Haemost 2004; 92: 929-39.
24. Petersen LC, Karpf DM, Agersø H, Hermit MB, Pelzer H, Persson E, Nichols T, Ezban M. Intravascular Inhibition of Factor VIIa and the Analogue NN1731 by Antithrombin. Br J Haematol 2010: doi:
25. Holmberg HL, Lauritzen B, Tranholm M, Ezban M. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice. J Thromb Haemost 2009; 7: 1517-22.
26. Johansen PB, Bjorn SE, Agerso H, Thorup I, Hermit MB, Sorensen B, Stennicke HR, Ezban M, Tranholm M. Prolonged effect of GlycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma. Thromb Haemost 2010;104: 157-64.
27. Stennicke HR, Ostergaard H, Bayer RJ, Kalo MS, Kinealy K, Holm PK, Sorensen BB, Zopf D, Bjorn SE. Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives. Thromb Haemost 2008; 100: 920-8.
28. Conard J, Brosstad F, Lie LM, Samama M, Abildgaard U. Molar antithrombin concentration in normal human plasma. Haemostasis 1983; 13: 363-8.